Benjamin Wenyuan Xie

Mr. Benjamin Wenyuan Xie


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2026 in Current Oncology
Verified
Journal Article
Open access
PDF file
JNJanki Rani Naidugari
Janki Rani Naidugari
SWShruti Wadhwa
Shruti Wadhwa
BXBenjamin Wenyuan Xie
Benjamin Wenyuan Xie
STSarah Marie Taheri
Sarah Marie Taheri
IKIndraneel Kulkarni
Indraneel Kulkarni
RRRebecca Redman
Rebecca Redman
Background: Macrophage migration inhibitory factor (MIF) is a critical modulator of the tumor immune microenvironment (TME). Its clinical significance in head and neck squamous cell carcinoma (HNSCC) remains controversial because of HPV-dependent tumor biology and the limitations of single-timepoint biomarker assessments. This preliminary study evaluates whether dynamic changes in circulating MIF (ΔMIF) in an HPV-stratified longitudinal cohort reflect disease severity and treatment response. Methods: Ninety-six serial serum samples were analyzed from 27 HNSCC patients (22 HPV-positive, 5 HPV-negative) from diagnosis through therapy and follow-up. Serum MIF and anti-HPV16 E7 IgG were quantified by ELISA, and ΔMIF was defined as the change in MIF concentration between consecutive visits. Results: Baseline MIF did not correlate with clinical stage in the total cohort (p = 0.63). However, 56% of HPV-positive patients exhibited a positive correlation between elevated MIF and advanced stage. Following chemoradiotherapy, the HPV-negative group showed a consistent and significant decline in MIF (mean ΔMIF = −1.23, p = 0.031), corresponding with no evidence of disease (NED). In contrast, the HPV-positive group showed heterogeneous trajectories (mean ΔMIF = +0.21, p = 0.94), with several patients demonstrating paradoxical declines in MIF during active disease or relapse, followed by recovery upon reaching NED. In select cases, MIF dynamics were closely synchronized with anti-E7 IgG levels. Conclusions: Serum MIF dynamics are strongly dependent on HPV status. While MIF serves as a reliable therapy-monitoring marker in HPV-negative HNSCC, it may play a complex and paradoxical immunomodulatory role in HPV-positive disease. These preliminary findings support the need for larger prospective, HPV-stratified trials.

25 November 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
JNJanki Rani Naidugari
Janki Rani Naidugari
SWShruti Wadhwa
Shruti Wadhwa
BXBenjamin Wenyuan Xie
Benjamin Wenyuan Xie
STSarah Marie Taheri
Sarah Marie Taheri
IKIndraneel Kulkarni
Indraneel Kulkarni
RRRebecca Redman
Rebecca Redman
Background: Macrophage migration inhibitory factor (MIF) shapes the tumor immune microen-vironment and has been implicated in head and neck squamous cell carcinoma (HNSCC), but its behavior may differ by HPV status. We evaluated whether dynamic changes in circulating MIF (ΔMIF) track disease severity and treatment response in HPV-positive (+) versus HPV-negative (-) HNSCC. Methods: In this single-center cohort study (n=27, 96 serial serum samples), clinical data were collected from diagnosis through therapy, remission, and relapse. MIF was quantified by ELISA and HPV status was assigned using p16 IHC, HPV DNA, and/or anti-E7 IgG. Associations with stage, treatment. and outcomes were analyzed using non-parametric/Fisher’s exact tests where appropriate. Results: At baseline (all patients), MIF did not correlate with clinical stage (p=0.63). Stratified analyses revealed heterogeneity: in HPV(+) patients (n=18 analyzable), 56% showed a direct cor-relation between high MIF levels and advanced stage disease, whereas HPV(−) patients (n=5) largely did not. Following concurrent cisplatin/radiation, HPV(−) patients demonstrated a consistent post-treatment decline in MIF (mean ΔMIF −1.23; p=0.031) and all achieved “no evidence of disease” status without recurrence. In contrast, HPV(+) patients showed mixed post-treatment MIF trajec-tories (mean ΔMIF +0.21; p=0.94). Over the full disease course, ΔMIF differed by HPV status (HPV(+) mean of +0.06 vs HPV(-) mean of −1.62; p=0.009. Conclusions: In HPV(-) HNSCC, post-treatment MIF decline strongly associates with effective response and remission, supporting MIF as a therapy-monitoring biomarker. In HPV(+) disease, baseline MIF may reflect severity, but post-treatment trajectories are heterogeneous and can decrease during active disease/relapse.